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The complexes [RuCp*(PP)Cl] (Cp* = C5Me5; [1], PP = dppm; [4], PP = Xantphos), 
[RuCp#(PP)Cl] (Cp# = C5Me4(CH2)5OH; [2], PP = dppm; [5], PP = Xantphos) and 
[RuCp*(dppm)(CH3CN)][SbF6] [3] were synthesized and evaluated in vitro as anticancer 
agents. Compounds 1-3 gave nanomolar IC50 values against normoxic A2780 and HT-29 cell 
lines, and were also tested against hypoxic HT-29 cells, maintaining their high activity. 
Complex 3 yielded an IC50 value of 0.55 ± 0.03 µM under a 0.1% O2 concentration.
Introduction 
Numerous organometallic (η6-arene)-ruthenium complexes 
have been screened as anticancer agents with promising results, 
for instance, compounds of the types [(η6-arene)Ru(NN)Cl]+ 
(NN = chelating nitrogen ligands, especially ethylenediamine 
(en)),1-3 [(η6-arene)Ru(NO)Cl] (NO = 3′-ﬂuorophenyl-3-
(phenylamino)-2-buten-1-one),4 [(η6-arene)Ru(OO)X] (OO = 3-
hydroxyflavone derivatives, X = Cl, Br or I)5, 6 or [(η6-
arene)Ru(pta)Cl2] (RAPTA) (pta = 1,3,5-triaza-7-
phosphatricyclo [3.3.1.1] decane).7, 8 Samuelson and co-
workers have published the use of η6-p-cymene ruthenium 
complexes with different diphosphines acting as either 
monodentate or chelating ligands, which showed good growth 
inhibitions against several cancer cell lines.9 In contrast, fewer 
examples of η5-cyclopentadienyl (Cp) or 
pentamethylcyclopentadienyl (Cp*) compounds have been 
biologically evaluated. Sava reported the synthesis and activity 
against TS/A adenocarcinoma of the compounds [(η5-
C5H5)Ru(pta)2Cl] and [(η
5-C5Me5)Ru(pta)2Cl], as equivalents to 
the RAPTA complexes.10 Compounds of the type [(η5-
C5H5)Ru(PP)L][X] (PP = 2 × PPh3 or 1,2-
bis(diphenylphosphino)ethane, L = planar nitrogen σ-bonded 
ligand and X = CF3SO3 or PF6) have been synthesised by 
Moreno et al. and some of them show better cytotoxicities than 
cisplatin.11-13 However, none of these Cp/Cp* ruthenium 
complexes has been tested under hypoxic conditions. Some 
diphosphines have demonstrated cytotoxicity against various 
cell lines,14 but it has been observed that, upon coordination to 
metals, diphosphines produce complexes with improved 
anticancer activity compared to the free ligands; a general 
hypothesis considers that the metal protects the ligands from 
oxidation before they interact with the corresponding biological 
target.15 
Here we present the results obtained from cell line assays 
carried out under normoxic and hypoxic conditions with 
ruthenium complexes containing chelating diphosphine ligands 
such as 1,1-bis(diphenylphosphino)methane (dppm) and 4,5-
bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos). The 
complexes have general structures [RuCp*(PP)Cl] (1, PP = 
dppm; 4, PP = Xantphos), [RuCp#(PP)Cl] (Cp# = 
C5Me4(CH2)5OH; 2, PP = dppm; 5, PP = Xantphos) and 
[RuCp*(PP)(CH3CN)][SbF6] (3, PP = dppm). We investigated 
the biological activity of both ligands and the effect of 
complexation. We were interested in assessing the impact of 
hydrophilic functionalisation of Cp* with an ‒OH group and 
the different cytotoxicities shown by analogous neutral and 
charged complexes. The anticancer activities were assessed 
against A2780 and HT-29 cell lines, for HT-29 both at 21% and 
0.1% O2 (hypoxic conditions) concentrations. 
 
Results and Discussion 
Complexes 1 and 4 were synthesised from [RuCp*Cl2]2, which 
was obtained following literature methods.16, 17 A similar 
method was employed for compounds 2 and 5, starting from the 
novel [RuCp#Cl2]2 complex (Scheme 1). This in turn was 
prepared by reaction of (5-hydroxypentyl)-
tetramethylcyclopentadiene18 with RuCl3 in ethanol at reflux. 
Compounds 119, 20 and 421 had been previously reported, but not 
biologically tested. Complex 3 was obtained from complex 1, 
acetonitrile and NaSbF6 in methanol at room temperature 
(Scheme 2). This method was adapted from the published 
synthesis of [RuCp*(PP)(CH3CN)][PF6] complexes, where PP 
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= chiral diphosphines.22 The structure of complex 3 was 
determined by single crystal X-ray diffraction. Compound 3 
crystallised in a triclinic cell from pentane/chloroform, and the 
structural solution was performed in the space group P?̅?. The 
asymmetric unit comprises one molecule of compound 3, 
including the counterion SbF6. The molecular structure of 3 is 
shown in Figure 1 and selected bond lengths and angles are 
given in Table 1. Compound 3 presents the characteristic piano-
stool geometry typical of η5- and η6-organometallic ruthenium 
species. The N(1)-C(11) triple bond length is 1.153(2) Å. 
 
 
 
 
 
 
 
 
 
 
Scheme 1. General synthesis of complexes 1, 2, 4 and 5. 
 
 
 
 
 
 
 
 
Scheme 2. Synthesis of complex 3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. ORTEP structure of complex 3 (cation) with thermal 
ellipsoids set at 50% probability. Hydrogen atoms omitted for clarity. 
 
The cytotoxic activities of compounds 1-5, along with cisplatin, 
dppm and Xantphos were tested on the A2780 and HT-29 cell 
lines after five-day exposures at 37 ºC and 21% O2. The IC50 
results are shown in Table 2. The most active complexes were 
those formed from dppm, 1, 2 and 3, all with better 
cytotoxicities, in the nanomolar range, than cisplatin for both 
HT-29 and A2780 cell lines. Dppm was active by itself, with 
IC50 values below 1.5 µM. However, 
1H and 31P NMR 
spectroscopy experiments in deuterated DMSO showed no de-
coordination of dppm from complexes 1 and 3 after five days. 
The observation that diphosphines do not dissociate is further 
reinforced by the fact that complexes 4 and 5 gave moderate to 
good activities, which are not due to a possible release of the 
ligand, because Xantphos did not show anticancer behaviour on 
its own. This contradicts the previous hypothesis that the 
activities of these types of diphosphine complexes depend on 
possible de-coordinations of the ligands.15 The extremely 
different behavior of dppm and Xantphos provides interesting 
material for further future studies. Complexes 4 and 5 were 
more active against A2780 cells, with IC50 values close to 
cisplatin. The presence of the (CH2)5OH chain in the Cp
# 
compounds 2 and 5 produced no great effect on their anticancer 
activities, compared to those of the Cp* complexes 1 and 4. 
The best cytotoxicity was observed for the positively charged 
complex 3. 
 
Table 1. Selected bond lengths [Å] and angles [°] in the structure of 
compound 3 with s.u.s. in parenthesis. 
 
Ru(1)-N(1) 2.0775(16) 
Ru(1)-P(1) 2.3201(6) 
Ru(1)-P(2) 2.3503(6) 
N(1)-C(11) 1.153(2) 
C(11)-C(12) 1.481(3) 
Ru(1)-Ring Centroid 1.884 
Ru(1)-C(Cp*) 2.25226 
P(1)-Ru(1)-P(2) 71.626(19) 
N(1)-C(11)-C(12) 178.5(2) 
C(11)-N(1)-Ru(1) 178.90(16) 
P(2)-C(13)-P(1) 93.53(8) 
 
 
 
 
 
To assess the extent of hydrolysis23 in complexes 1 and 3, 10 
mM samples of both complexes in 0.6 ml of deuterated solvent 
(90% deuterated DMSO + 10% deuterium oxide) were prepared 
in NMR tubes and analysed by 1H NMR spectroscopy every 24 
hours during five days at room temperature. A new set of peaks 
at 5.14 and 1.61 ppm appeared gradually in both samples (see 
Fig. S1 and S4 in the ESI). The new species formed, after five 
days, in 48% yield from complex 1 and in 67% yield from 
complex 3. Mass spectrometry of this new species showed the 
same peaks observed for the chloride complex 1, where the 
chloride ligand was lost. By inference, the new species is 
believed to be the aqua species, which entails that monocationic 
complex 3 hydrolyses to a higher extent under the same 
conditions, and this coincides with its higher anticancer 
activity. 31P and 13C NMR analyses of both samples were also 
run when they were freshly prepared and after 5 days. 31P NMR 
spectra show a new peak at 5.08 ppm for both complexes 1 and 
3 (see Fig. S2 and S5 in the ESI). This discards the possibility 
of dppm de-coordination, given that free dppm shows a 
characteristic peak at -23 ppm in 90% deuterated DMSO + 10% 
deuterium oxide. 13C NMR spectra show new peaks at 94.9 and 
10.7 ppm after 5 days for complexes 1 and 3 (see Fig. S3 and 
S6 in the ESI). Neither 1H nor 13C NMR spectra show new 
peaks for the methyl groups of coordinated DMSO, which rules 
out the formation of a DMSO complex during the 5-days period 
of these experiments. 
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Table 2 gives the IC50 results obtained for the most active 
compounds 1-3 against hypoxic HT-29 cells at an oxygen 
concentration of 0.1%. Cancerous cells are known to proliferate 
within hypoxic environments, with oxygen content below 2%,24 
therefore hypoxic experiments tend to reproduce the conditions 
found in human solid tumours. Apart from cisplatin, whose 
activity remains practically unmodified, tirapazamine, a drug 
known to be hypoxia sensitive,25 was also employed as 
reference. Interestingly, the IC50 of dppm under hypoxic 
conditions increased considerably from 1.47 µM to 17.19 µM. 
A possible explanation for this is that the active species might 
be an oxidized form of dppm. However, Samuelson et al. have 
reported that, while dppm is moderately active against H460 
lung cells (IC50 = 18.2 μM), mono-oxidised dppm shows no 
cytotoxic activity (IC50 > 250 μM),
9 and similar conclusions 
had been drawn by Sadler et al.14 The activities of complexes 1-
3 improved slightly at a low O2 concentration. Complex 3 
showed again the best performance, with an IC50 of 0.55 ± 0.03 
µM, and is of particular significance and interest. 
 
Table 2. IC50 values (average of three replicates) for complexes 1-5 
along with cisplatin, tirapazamin, dppm and Xantphos. The drugs were 
incubated for 5 days at 37 ºC. The final concentration of 
dimethylsulfoxide was 0.1% (v/v) in each cell plate. 
 
 IC50 (µM) at 21% O2 
IC50 (µM) at 
0.1% O2 
Compound A2780  HT-29  HT-29  
Cisplatin 1.4 ± 0.3  2.52 ± 0.09  2.4 ± 0.4  
Tirapazamine -  31 ± 3  2.8 ± 0.4  
dppm 1 ± 1  1.47 ± 0.02  17.19 ± 0.08  
1 1.1 ± 0.2  0.73 ± 0.05  0.66 ± 0.03  
2 0.9 ± 0.1  0.791 ± 0.007  0.76 ± 0.03  
3 0.70 ± 0.02  0.61 ± 0.01  0.55 ± 0.03  
Xantphos >250  >250  -  
4 3.6 ± 0.4  10.1 ± 0.5  -  
5 4.0 ± 0.3  11.9 ± 0.7  -  
 
Conclusions 
In summary, a series of Cp*-based diphosphine ruthenium 
complexes (1-5) was prepared and biologically tested against 
A2780 and HT-29 cancerous cell lines. Both normoxic and 
hypoxic studies showed activities in the nanomolar range. The 
best anticancer activity was obtained with complex 3, which 
maintained a low IC50 value even under hypoxic conditions 
with 0.1% O2 concentration, and showed a higher degree of 
hydrolysis than its neutral analogue 1 under the same 
conditions. Future studies could include cationic versions of 2, 
4, 5 and similar complexes to check whether they are generally 
more effective. Testing other free and coordinated phosphines 
and phosphine oxides could shed some light on the effect that 
the oxidation state and structure of the ligand have on cytotoxic 
activity. 
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Experimental 
General 
All of the manipulations for the syntheses of complexes 1-5 and 
[RuCp#Cl2]2 were conducted using standard Schlenk line 
techniques under an inert atmosphere of dry dinitrogen in a dual 
vacuum/dinitrogen line. Dry dinitrogen was obtained by 
passing dinitrogen gas through a double column with 
phosphorus pentoxide and activated 4 Å molecular sieves. All 
of the 1H, 31P and 13C NMR spectra were recorded using a 
Bruker DPX (300 MHz) or a Bruker DRX (500 MHz) 
spectrometers. Microanalyses were obtained at the University 
of Leeds Microanalytical Service. Mass spectra were obtained 
at the University of Leeds Mass Spectrometry Service. 
[RuCp*Cl2]2
16, 17 and (5-hydroxypentyl)-
tetramethylcyclopentadiene18 were prepared according to 
literature methods. All other reagents are commercially 
available and were used as received. Complexes 119, 20 and 421 
had already been reported in the literature and were synthesised 
with the same general method used for compounds 2 and 5. 
X-Ray Crystallography 
A suitable single crystal was selected under the microscope and 
immersed in inert oil. The crystal was mounted on a glass 
capillary and attached to a goniometer head on a Bruker X8 
Apex diffractometer using graphite monochromated Mo-Kα 
radiation (λ = 0.71073 Å) and 1.0° Φ-rotation frames. The 
crystal was cooled to 150 K by an Oxford cryostream low 
temperature device.26 The full data sets were recorded and the 
images processed using the Apex2 software, Bruker Nonius 
2004. Structure solution by direct methods was achieved 
through the use of the SHELXS-97 program,27 and the 
structural model refined by full matrix least squares on F2 using 
SHELXL-97.27 Editing of Crystallographic Information Files 
(CIFs) and construction of tables of bond lengths and angles 
were achieved using WC.28 Hydrogen atoms were placed using 
idealised geometric positions (with free rotation for methyl 
groups), allowed to move in a “riding model” along with the 
atoms to which they were attached, and refined isotropically. 
Cell Line Testing 
The in vitro normoxic studies were performed at the Institute of 
Cancer Therapeutics, Bradford, on the cell lines A2780 (human 
ovarian carcinoma) and HT29 (human colon carcinoma). Cells 
were incubated in 96-well plates at a cell concentration of 2.0 x 
104 cells/mL.  Complete cell medium containing RPMI-1640, 
supplemented with 10% foetal calf serum, sodium pyruvate (1 
mM) and L-glutamine (2 mM), was used to prepare the desired 
cell concentration and reference wells. Plates containing cells 
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were incubated for 24 hours at 37 °C in an atmosphere of 21% 
O2 and 5% CO2, prior to drug exposure. All compounds were 
dissolved in dimethylsulfoxide to give an initial concentration 
of 25 mM and diluted further with cell medium to obtain 
concentrations ranging from 250-0.49 µM. A final 
dimethylsulfoxide concentration of 0.1% (v/v) was obtained, 
which is non-toxic to cells. 100 µL of cell medium was added 
to the reference cells and 100 µL of differing concentrations of 
drug solution were added to the remaining wells. The plates 
were incubated for a further 5 days at 37 °C in an atmosphere 
of 5% CO2. 20 µL of 3-(4,5-dimethylthiazol-1-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution (5 mg/mL) was 
added to each well and incubated for a further 3 hours at 37 °C 
in an atmosphere of 5% CO2. Upon completion, all solutions 
were removed from the wells via pipette, and 150 µL of 
dimethylsulfoxide was added to each well to dissolve the purple 
formazan crystals. A Thermo Scientific Multiskan EX 
microplate photometer was used to measure the absorbance at 
540 nm. Lanes containing 100% cell medium and 100% cell 
solution were used as a blank and 100% cell survival 
respectively. Cell survival was determined as the absorbance of 
treated cells minus the blank cell medium, divided by the 
absorbance of the 100% cell solution; this value was expressed 
as a percentage. The IC50 values were determined from a plot of 
percentage cell survival against drug concentration (µM), and 
each experiment was carried out three times to obtain average 
IC50 values. The in vitro hypoxic studies were carried out on 
HT-29 cells following a similar procedure, but in this case the 
cells were incubated in a Don Whitley Scientific H35 
Hypoxystation, kept at 37°C with an O2 concentration of 0.1%. 
Synthesis of [RuCp#Cl2]2 
(5-Hydroxypentyl)-tetramethylcyclopentadiene (3.14 g, 15.1 
mmol) was added to a solution of RuCl3 ∙ 3H2O (1.73 g, 6.62 
mmol) in dry ethanol (50 ml) and the mixture was stirred and 
heated to reflux under nitrogen for three hours. After that, it 
was concentrated and left in the freezer overnight, which 
resulted in precipitation of an orange solid. This was filtered, 
washed with dry hexane (×3), dried under vacuum and kept in 
the glove box (1.214 g, 3.20 mmol, 48%). Calculated for 
[C14H23Cl2ORu] (379.25 g mol
-1): C 44.3; H 6.1; Cl 18.7% 
Found: C 44.7; H 6.3; Cl 18.3%. 1H NMR (CDCl3, 500.57 
MHz, 300.0 K): δ 5.11 [br. s, 6H, C5(CH3)4(CH2)5OH], 4.15 
[br. s, 6H, C5(CH3)4(CH2)5OH], 4.09 [m, 4H, 
C5(CH3)4(CH2)5OH], 3.35 [br. s, 2H, C5(CH3)4(CH2)5OH], 2.73 
[br. s, 2H, C5(CH3)4(CH2)5OH], 2.29 [m, 2H, 
C5(CH3)4(CH2)5OH]; 
13C{1H} NMR (CDCl3,  125.77 MHz,  
299.2 K): δ 142.3 [C5(CH3)4(CH2)5OH], 135.3 
[C5(CH3)4(CH2)5OH], 128.2 [C5(CH3)4(CH2)5OH], 63.3 
[C5(CH3)4(CH2)5OH], 33.7 [C5(CH3)4(CH2)5OH], 27.2 
[C5(CH3)4(CH2)5OH], 24.6 [C5(CH3)4(CH2)5OH], 12.5 
[C5(CH3)4(CH2)5OH], 11.8 [C5(CH3)4(CH2)5OH]. 
Synthesis of 2 
1,1'-Bis(diphenylphosphino)methane (0.29 g, 0.75 mmol) was 
added to a solution of [Ru(C5Me4(CH2)5OH)Cl2]2 (0.19 g, 0.5 
mmol) in dry dichloromethane (100 ml) and the mixture was 
stirred under nitrogen overnight. The solvent was evaporated to 
give a brown residue, which was extracted with diethyl ether 
(×2). The orange ether extract was concentrated and left in the 
freezer. A precipitate formed, which was then filtered. The 
obtained filtrate was evaporated to give an orange solid, and 
this was recrystallised from dichloromethane/hexane (0.1184 g, 
0.163 mmol, 33%). Calculated for C39H45ClOP2Ru (727.87 g 
mol-1): C 64.3; H 6.2; Cl 4.9% Found: C 64.1; H 6.3; Cl 5.1%. 
1H NMR (C6D5CD3, 500.57 MHz, 300.0 K): δ 7.64-6.82 [20H, 
(C6H5)4P2CH2], 4.47 [dt, 
2J(H-H) = 14.5 Hz, 
2J(H-P) = 9.4 Hz, 1H, 
(C6H5)4P2CH2], 4.22 [dt, 
2J(H-H) = 14.2 Hz, 
2J(H-P) = 11.3 Hz, 1H, 
(C6H5)4P2CH2], 3.26 [t, 
3J(H-H) = 6.2 Hz, 2H, 
C5(CH3)4(CH2)4CH2OH], 2.23 [m, 2H, 
C5(CH3)4(CH2)4CH2OH], 1.81 [t, 
4J(H-P) = 1.9 Hz, 6H, 
C5(CH3)4(CH2)4CH2OH], 1.79 [t, 
4J(H-P) = 2.0 Hz, 6H, 
C5(CH3)4(CH2)4CH2OH], 1.36 [quint, 
3J(H-H) = 7.6 Hz, 2H, 
C5(CH3)4(CH2)4CH2OH], 1.25 [m, 4H, 
C5(CH3)4(CH2)4CH2OH]; 
31P{1H} NMR (C6D5CD3, 121.49 
MHz, 300.0 K):  δ 12.38 [s]; 13C{1H} NMR (C6D5CD3, 125.77 
MHz,  299.2 K): δ 137.5 [s, (C6H5)4P2CH2], 133.7 [t, 
2,3J(C-P) = 
5.4 Hz, (C6H5)4P2CH2], 133.0 [t, 
2,3J(C-P) = 5.4 Hz, 
(C6H5)4P2CH2], 92.6 [m, C5(CH3)4(CH2)4CH2OH], 89.1 [t, 
2J(C-
P) = 2.6 Hz, C5(CH3)4(CH2)4CH2OH], 87.9 [t, 
2J(C-P) = 2.6 Hz, 
C5(CH3)4(CH2)4CH2OH], 62.6 [s, C5(CH3)4(CH2)4CH2OH], 
49.2 [t, 1J(C-P) = 19.2 Hz, (C6H5)4P2CH2], 33.1 [s, 
C5(CH3)4(CH2)4CH2OH], 30.8 [s, C5(CH3)4(CH2)4CH2OH], 
26.6 [s, C5(CH3)4(CH2)4CH2OH], 26.4 [s, 
C5(CH3)4(CH2)4CH2OH], 10.9 [s, C5(CH3)4(CH2)4CH2OH], 
10.8 [s, C5(CH3)4(CH2)4CH2OH]. ES MS (+): m/z 693.2 [M – 
Cl]+. 
Synthesis of 3 
Dry methanol (80 ml) and dry acetonitrile (4 ml) were added to 
a mixture of complex 1 (0.15 g, 0.23 mmol) and NaSbF6 (0.6 g, 
2.3 mmol) under nitrogen. The initial orange suspension 
changed to a light yellow solution, and this was stirred 
overnight. The solvent was evaporated and the residue treated 
with dichloromethane and filtered. The filtrate was 
concentrated and, after adding diethyl ether and placing the 
mixture in the freezer for some hours, the light yellow 
precipitate formed was filtered off, washed with diethyl ether 
and dried (0.1597 g, 0.178 mmol, 77%). Calculated for 
C37H40F6NP2RuSb (897.07 g mol
-1): C 49.5; H 4.5; N 1.6% 
Found: C 49.6; H 4.6; N 1.5%. 1H NMR (CD2Cl2, 300.13 MHz, 
300.0 K): δ 7.49 [m, 16H, (C6H5)4P2CH2], 7.36 [m, 4H, 
(C6H5)4P2CH2], 5.13 [dt, 
2J(H-H) = 16 Hz, 
2J(H-P) = 9.8 Hz, 1H, 
(C6H5)4P2CH2], 4.37 [dt, 
2J(H-H) = 16 Hz, 
2J(H-P) = 10.5 Hz, 1H, 
(C6H5)4P2CH2], 1.64 [t, 
5J(H-P) = 1.7 Hz, 3H, CH3CN], 1.59 [t, 
4J(H-P) = 2.2 Hz 15H, C5(CH3)5]; 
31P{1H} NMR (CD2Cl2, 121.49 
MHz, 300.0 K): δ 9.56 [s]; 13C{1H} NMR (CD2Cl2, 125.88 
MHz,  300.0 K): δ 155.9 [s, CH3CN], 132.8 [m, (C6H5)4P2CH2], 
131.9 [t, 2,3J(C-P) = 5.2 Hz, (C6H5)4P2CH2], 131.2 [d, 
1J(C-P) = 
32.7 Hz, (C6H5)4P2CH2], 129.3 [dt, 
2,3J(C-P) = 18.7, 5.2 Hz, 
(C6H5)4P2CH2], 92.0 [s, C5(CH3)5], 51.3 [s, (C6H5)4P2CH2], 
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10.2 [s, C5(CH3)5], 3.8 [s, CH3CN]. ES MS (+): m/z 662.2 [M-
SbF6]
+. 
Synthesis of 5 
4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene (0.43 g, 0.75 
mmol) was added to a solution of [Ru(C5Me4(CH2)5OH)Cl2]2 
(0.19 g, 0.5 mmol) in dry dichloromethane (100 ml) and the 
mixture was stirred under nitrogen overnight. The solvent was 
evaporated to give a brown residue, which was extracted with 
diethyl ether (×4). The yellow ether extract was concentrated 
and left in the freezer overnight. The precipitate formed was 
filtered, and the orange filtrate evaporated. The residue was 
recrystallised from dichloromethane/hexane to give a yellow 
solid (0.0897 g, 0.097 mmol, 19%). Calculated for 
C53H55ClO2P2Ru (921.94 g mol
-1): C 69.0; H 6.0; Cl 3.9% 
Found: C 68.3; H 6.1; Cl 4.3%. 1H NMR (C6D5CD3, 300.13 
MHz, 300.0 K): δ 8.20-6.49 [26H, 
(C6H5)4P2OC(CH3)2(C6H3)2], 3.15 [t, 
3J(H-H) = 6.2 Hz, 2H, 
C5(CH3)4(CH2)4CH2OH], 1.64 [s, 3H, 
(C6H5)4P2OC(CH3)2(C6H3)2], 1.59 [s, 3H, 
(C6H5)4P2OC(CH3)2(C6H3)2], 1.57 [br. s, 6H, 
C5(CH3)4(CH2)4CH2OH], 1.29 [m, 2H, 
C5(CH3)4(CH2)4CH2OH], 0.98 [br. s, 6H, 
C5(CH3)4(CH2)4CH2OH], 0.85 [m, 4H, 
C5(CH3)4(CH2)4CH2OH], 0.45 [m, 2H, 
C5(CH3)4(CH2)4CH2OH]; 
31P{1H} NMR (C6D5CD3, 202.63 
MHz, 300.0 K): δ 33.26 [s]; 13C{1H} NMR (C6D5CD3, 125.77 
MHz,  299.2 K): δ 137.5 [(C6H5)4P2OC(CH3)2(C6H3)2], 92.4 [s, 
C5(CH3)4(CH2)4CH2OH], 62.5 [s, C5(CH3)4(CH2)4CH2OH], 
36.8 [s, (C6H5)4P2OC(CH3)2(C6H3)2], 32.0 [s, 
C5(CH3)4(CH2)4CH2OH], 30.7 [s, C5(CH3)4(CH2)4CH2OH], 
30.3 [s, (C6H5)4P2OC(CH3)2(C6H3)2], 26.7 [s, 
C5(CH3)4(CH2)4CH2OH], 23.6 [s, C5(CH3)4(CH2)4CH2OH], 
23.1 [s, (C6H5)4P2OC(CH3)2(C6H3)2], 9.6 [s, 
C5(CH3)4(CH2)4CH2OH], 9.2 [s, C5(CH3)4(CH2)4CH2OH]. ES 
MS (+): m/z 922.2 [M]+; 887.3 [M-Cl]+. 
Hydrolysis Studies 
Complexes 1 and 3 (0.006 mmol) were dissolved in deuterated 
DMSO (0.54 ml, 90%) and deuterium oxide (0.06 ml, 10%) to 
give 0.6 ml of 10 mM solutions, in NMR tubes. The fresh 
samples were analysed by 1H, 31P and 13C NMR spectroscopy 
at 300.0 K with a Bruker DPX 300.13 MHz spectrometer. 31P 
and 13C NMR analyses were repeated after five days. 1H NMR 
analyses were repeated every 24 hours within that 5-days 
period. 
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